{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T01:01:47Z","timestamp":1782867707901,"version":"3.54.5"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008478","name":"Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Limited evidence exists on prevailing treatments, disease characteristics and real-world outcomes of patients with alopecia areata (AA), particularly for those with \u2265 50% scalp hair loss (SHL) managed in clinical settings outside the USA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To provide evidence on disease characteristics, clinical management and outcomes of patients with AA with \u2265 50% SHL from real-world practice settings in Europe.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Assessment of real-world Disease characteristics and outcomes in Alopecia Areata in a Global non-Interventional Observational cohort (ADAAGIO) study was a retrospective chart review study in the UK, France, Spain and Germany. Adults and adolescents with \u2265 50% SHL were included. The first clinical observation of \u2265 50% SHL defined the study index date (2015\u20132019). Patients had \u2265 6\u2005months of follow-up from index. Analyses were descriptive. The primary endpoint was the absolute Severity of Alopecia Tool (SALT) score, assessed longitudinally. Other endpoints included change in SALT score from baseline, and sustained SALT \u2264 20, defined as time to achieving SALT \u2264 20 without regression to SALT &amp;gt; 30 within 6\u2005months, and sustained SALT \u2264 20 was assessed via inverse probability of censoring weighting (IPCW)-adjusted Kaplan\u2013Meier estimation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 741 patients were included [median age at index: 27\u2005years (range 12\u201381); 52.6% (390\/741) female]. The mean SALT score at index was 63.5 (SD 15.6); 80.2% (594\/741) had patchy AA and 19.8% (147\/741) had alopecia totalis or universalis. Topical corticosteroids were the most common treatment post-index, with 55.6% (412\/741) receiving \u2265 1 course with a median cumulative exposure of 4\u2005months. Systemic and intralesional corticosteroids [44.1% (327\/741) and 22.5% (167\/741), respectively], Systemic and intralesional corticosteroids [44.1% (327\/741) and 22.5% (167\/741), respectively], systemic were also common. The mean absolute SALT reduction at 12\u2005months post-index was \u201344.6% (SD 37.3%). However, at 12\u2005months, based on IPCW-adjusted estimation, few patients (10.6%) achieved SALT \u2264 20 that was sustained for \u2265 6\u2005months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although patients in this study experienced substantial absolute SALT score reductions, few achieved and sustained SALT \u2264 20. These findings highlight the potential suboptimal effectiveness of the varied treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llaf319","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T11:37:41Z","timestamp":1754393861000},"page":"42-51","source":"Crossref","is-referenced-by-count":1,"title":["Findings from the Assessment of real-world Disease characteristics and outcomes in Alopecia Areata in a Global non-Interventional Observational cohort (ADAAGIO) study"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0044-7107","authenticated-orcid":false,"given":"Keith L","family":"Davis","sequence":"first","affiliation":[{"name":"RTI Health Solutions, Research Triangle Park , NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1424-8069","authenticated-orcid":false,"given":"Andrew","family":"Messenger","sequence":"additional","affiliation":[{"name":"University of Sheffield , Sheffield ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Va\u00f1\u00f3-Galv\u00e1n","sequence":"additional","affiliation":[{"name":"Trichology Unit of the Ram\u00f3n y Cajal University Hospital and the Trichology and Hair Transplant Unit of Pedro Ja\u00e9n Group Clinic, University of Alcal\u00e1 , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Tran","sequence":"additional","affiliation":[{"name":"Pfizer, Inc. , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Napatalung","sequence":"additional","affiliation":[{"name":"Pfizer, Inc. , New York, NY ,","place":["USA"]},{"name":"Icahn School of Medicine at Mount Sinai , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent A","family":"Hanson","sequence":"additional","affiliation":[{"name":"Pfizer, Inc. , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizzi","family":"Esterberg","sequence":"additional","affiliation":[{"name":"RTI Health Solutions, Research Triangle Park , NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest H","family":"Law","sequence":"additional","affiliation":[{"name":"Pfizer, Inc. , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"2025122312175366400_llaf319-B1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/bjd.20628","article-title":"The epidemiology of alopecia areata: a population-based cohort study in UK primary care","volume":"186","author":"Harries","year":"2022","journal-title":"Br J Dermatol"},{"key":"2025122312175366400_llaf319-B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2017.04.1141","article-title":"Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis","volume":"78","author":"Strazzulla","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2025122312175366400_llaf319-B3","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2023.0002","article-title":"Trends in prevalence and incidence of alopecia areata, alopecia totalis, and alopecia universalis among adults and children in a US employer-sponsored insured population","volume":"159","author":"Mostaghimi","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2025122312175366400_llaf319-B4","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/bjd\/ljae058","article-title":"Global, regional, and national epidemiology of alopecia areata: a systematic review and modelling study","volume":"119","author":"Jeon","year":"2024","journal-title":"Br J Dermatol"},{"key":"2025122312175366400_llaf319-B5","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/ced\/llac025","article-title":"Global Guidelines in Dermatology Mapping Project (GUIDEMAP): a systematic review of alopecia areata clinical practice guidelines","volume":"48","author":"Asfour","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"2025122312175366400_llaf319-B6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jaad.2020.03.004","article-title":"The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata","volume":"83","author":"Meah","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025122312175366400_llaf319-B7","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"key":"2025122312175366400_llaf319-B8","author":"Senna"},{"issue":"Suppl","key":"2025122312175366400_llaf319-B9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jaad.2022.06.237","article-title":"Efficacy and safety of the oral JAK3\/TEC inhibitor ritlecitinib in adolescents with alopecia areata: results from the ALLEGRO Phase 2b\/3 randomized, double-blind, placebo-controlled trial","volume":"87","author":"Hordinsky","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2025122312175366400_llaf319-B10","doi-asserted-by":"crossref","first-page":"e0140817","DOI":"10.1371\/journal.pone.0140817","article-title":"Completeness of follow-up determines validity of study findings: results of a prospective repeated measures cohort study","volume":"10","author":"von Allmen","year":"2015","journal-title":"PLOS ONE"},{"key":"2025122312175366400_llaf319-B11","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/01.ede.0000135174.63482.43","article-title":"A structural approach to selection bias","volume":"15","author":"Hern\u00e1n","year":"2004","journal-title":"Epidemiology"},{"key":"2025122312175366400_llaf319-B12","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1177\/1740774507081224","article-title":"Estimation of treatment effect adjusting for dependent censoring using the IPCW method: an application to a large primary prevention study for coronary events (MEGA study)","volume":"4","author":"Yoshida","year":"2007","journal-title":"Clin Trials"},{"key":"2025122312175366400_llaf319-B13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10985-022-09564-6","article-title":"On logistic regression with right censored data, with or without competing risks, and its use for estimating treatment effects","volume":"29","author":"Blanche","year":"2023","journal-title":"Lifetime Data Anal"},{"key":"2025122312175366400_llaf319-B14","doi-asserted-by":"crossref","first-page":"107440","DOI":"10.1016\/j.cct.2024.107440","article-title":"Comparison of baseline covariate adjustment methods for restricted mean survival time","volume":"138","author":"Hanada","year":"2024","journal-title":"Contemp Clin Trials"},{"key":"2025122312175366400_llaf319-B15","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1177\/1536867X0400400403","article-title":"Controlling for time-dependent confounding using marginal structural models","volume":"4","author":"Fewell","year":"2004","journal-title":"Stata J"},{"key":"2025122312175366400_llaf319-B16","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s13555-022-00711-3","article-title":"Defining severity in alopecia areata: current perspectives and a multidimensional framework","volume":"12","author":"King","year":"2022","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf319\/64288628\/llaf319.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/1\/42\/64288628\/llaf319.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/1\/42\/64288628\/llaf319.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T17:18:00Z","timestamp":1766510280000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/1\/42\/8256374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,10,9]]},"published-print":{"date-parts":[[2025,12,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf319","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,10,9]]}}}